View Older Stories View More Recent Stories
-
BMO Capital Reiterates Outperform Rating on Ionis Pharmaceuticals (IONS)
-
BMO Capital Reiterates Outperform Rating on Ionis Pharmaceuticals (IONS)
-
BMO Capital Reiterates Outperform Rating on Ionis Pharmaceuticals (IONS)
-
Ionis Pharmaceuticals (IONS) Reports Strong 1Q, Eplontersen PN Data Soon - BMO Capital
-
Ionis Pharmaceuticals (IONS) PT Raised to $90 at BMO Capital, Following Earnings
-
Ionis Pharmaceuticals (IONS) PT Trimmed to $85 at BMO Capital
-
BMO Capital Maintains Rating, PT on Ionis Pharmaceuticals (IONS) Despite Lower Spinraza Sales
-
Ionis Pharmaceuticals (IONS) PT Lowered to $95 at BMO Capital, Lowers Spinraza Estimates
-
Ionis Pharmaceuticals (IONS) PT Raised to $96 at BMO Capital
-
Ionis Pharmaceuticals (IONS) PT Raised to $82 at BMO Capital
-
Ionis Pharmaceuticals (IONS) PT Lowered to $74 at BMO Capital
-
Ionis Pharmaceuticals (IONS) PT Raised to $75 at BMO Capital on Expanded Biogen Deal
-
Ionis Pharmaceuticals to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference
-
Ionis Pharmaceuticals (IONS) Selling Pressure 'Unwarranted' - BMO
-
Ionis Pharmaceuticals (IONS) PT Raised to $69 at BMO Capital on 2Q; 'Tempering Better Economics Given Uncertainty Risk'
-
Ionis Pharmaceuticals (IONS) PT Raised to $67 at BMO Capital; Buy on Weakness
-
Ionis (IONS) Partner Biogen Reports Blow-Out Spinraza Sales - BMO Capital
-
Akcea Therapeutics (AKCA) Closes IPO, Reports $50M Private Placement with Novartis Pharma (NVS)
-
Akcea Therapeutics Announces Closing of Initial Public Offering
-
Akcea Therapeutics Announces Pricing of Initial Public Offering
-
Ionis Pharmaceuticals (IONS) PT Raised to $62 at BMO Capital; 'NEURO QoL Data Illustrate Inotersen Benefit'
-
Akcea Therapeutics (AKCA) Launches Proposed IPO with Initial Offering Price of $12 to $14/Share (IONS)
-
Akcea Therapeutics Launches Proposed Initial Public Offering
-
UPDATE: Ionis Pharma (IONS) Defended at BMO Capital - FDA Warning Letter Is Unwarranted
-
BMO Reiterates Bullish View on Ionis Pharmaceuticals (IONS) as Spinraza Partner Biogen Reports Strong Start
-
Ionis Pharmaceuticals (IONS) PT Lowered to $59 at BMO Capital on Volanesorsen Data; 'Compliance Rate to 75% from 85%'
-
BMO Maintains Outperform Rating and $63 PT on Ionis Pharmaceuticals (IONS); Bayer FXI-Rx Expansion
-
Ionis Pharma (IONS): Cutting PT But Improving Fundamentals - BMO
-
Ionis Pharma (IONS): Data Confirms Positive Outlook - BMO Capital
-
Ionis Pharmaceuticals (IONS) PT Raised to $68 at BMO Capital
-
BMO Capital Sees Ionis Pharma (IONS) and Biogen (BIIB) Trading Higher Following Broad Spinraza Approval
-
Ionis Pharmaceuticals (IONS) PT Raised to $61 at BMO Capital
-
Ionis Pharmaceuticals to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference
-
Today's Biotech Upside Could Be Just the Start - BMO Capital (IBB) (XBI)
-
Streetinsider.com's Hot Lunchtime Reads 11/7: (WATT) (ACIA) (LC) (IONS)
-
Ionis Pharmaceuticals (IONS) Bullish View Reiterated at BMO Capital Following Spinraza Update
-
Ionis Pharma (IONS): Data Presentations Increase Confidence - BMO
-
BMO Capital Upgrades Ionis Pharmaceuticals (IONS) to Outperform; To Benefit form Alnylam Failure
-
Vertex (VRTX), BioMarin (BMRN), Intercept (ICPT), Others Highlighted as Targets at BMO Following PFE/MDVN
-
Notable Analyst Rating Changes 8/3: (ZNGA) (NMBL) (AVD) Upgraded; (CSIQ) (EQR) (EMR) Downgraded
-
Ionis Pharmaceuticals (IONS) PT Raised to $40 at BMO Capital
-
Ionis Pharma (IONS): Benson TTR-Rx Data Support Benefit in FAC and WT - BMO
-
Ionis Pharma (IONS): Two More SMA Events Could Dampen Interim Look - BMO
-
Notable 52-Week Highs and Lows 5/27: (BIG) (VEEV) (ULTA) High; (BIOC) (IONS) (IPCI) Low
-
BMO Capital Downgrades Ionis Pharmaceuticals (IONS) to Market Perform
-
Ionis Pharma (IONS): CARDIO-TTR Trial Uncertainty as GSK Stops Initiation - BMO
-
Streetinsider.com's Hot Lunchtime Reads 4/7: (FB) (TSLA) (IONS) (BBBY)
-
BMO Capital Sees Attractive Entry Point in Ionis (IONS) Amid Sell-Off; Says NEURO-TTR Study Unaffected By Hold
-
BMO Capital Starts Ionis Pharmaceuticals (IONS) at Outperform

